WO2005011648A2 - Use of cyclic bioisosteres of purine system derivatives for the treatment diseases caused by disorders of nitrergic and dopaminergic systems - Google Patents
Use of cyclic bioisosteres of purine system derivatives for the treatment diseases caused by disorders of nitrergic and dopaminergic systems Download PDFInfo
- Publication number
- WO2005011648A2 WO2005011648A2 PCT/RU2004/000298 RU2004000298W WO2005011648A2 WO 2005011648 A2 WO2005011648 A2 WO 2005011648A2 RU 2004000298 W RU2004000298 W RU 2004000298W WO 2005011648 A2 WO2005011648 A2 WO 2005011648A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- pyridazine
- salt
- dione
- sodium salt
- dyne
- Prior art date
Links
- 0 CC(*[C@@](C)C1O)C1O Chemical compound CC(*[C@@](C)C1O)C1O 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
- C07D237/30—Phthalazines
- C07D237/32—Phthalazines with oxygen atoms directly attached to carbon atoms of the nitrogen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
Definitions
- Nitrogen Oxide ⁇ - a low-molecular gas that is free from harmful substances - is easily penetrated by cell membranes and is highly selective, which is very The influence of ⁇ on the state of the carcass depends to a large extent on the amount of gas.
- An activated enzyme synthesizes a cyclic guanosine (hereinafter referred to as cryptophysiography), which regulates the process of membranes and Larger concentra tions produced by the macrophage of ⁇ synthase can be reflected on the effects of the animal directly (directly).
- ⁇ participates in the regulation of neurotransmission in the central non-invasive system, in particular, through the use of non-synaptic interactions, regulating the minesystemic systems.
- the system is reterion not directly related to basic neuropsychiatric diseases, such as depression, disease, and Parkinson’s disease.
- Dopamine (hereinafter ⁇ ) is the most important neuromedia and neuro-modulator, which plays an important role in organism.
- the central non-neglective system ⁇ participates in motion control, cognitive functions, emotional features, neutral secrets, and the mains card functions. In the case of empire ⁇ it participates in the regulation of a hostess, a vessel of a tune, and a section of a city.
- benzotropyrpyrpyridine for the induction of antipyretic, antidepressant and antidiaminic activity in the body is 118 (45).
- the known application of the 4 ', 8-bis-hydrosulphide and its salts in the form of drugs with rythropegic activity ( ⁇ , 4600714,.
- the use of (1,2,5,6-tetrahydro-1-alkyl-3-pyridinyl) -2-thiazlamines and 4- (hexahydro-1-alkyl-3-pyridinyl) -2-drugs is recommended for the treatment of , high blood pressure, diseases of the Republic of Ukraine, hypersensitivity, sexual disorders and amegaly (08, 46508054, ⁇ ).
- Substituted 1- (alkoxyphenyl) pyrazines are known to be partial agonists of dopamine, which should be used for the treatment of disorders of dopamine and treatment of the disease in Pakistan, 15, 28.
- ⁇ a ⁇ zhe ⁇ , ⁇ '-dvu ⁇ zameschennye ⁇ izv ⁇ dnye benzimidaz ⁇ l ⁇ na W, 6,521,623, ⁇
- SIGNIFICANT FOX (DR. 26) 7 proved the presence of specific therapeutic activity in models for live or clinical trials.
- Influence of compounds according to the invention on the dysfunctional system may be indicated due to changes in the distribution of the electri-
- the additional effect of these compounds on other types of preparations, for example, adenosine, may mediate an active activity of the amphipods.
- ⁇ ⁇ - ⁇ , - ⁇ 2 , - ⁇ , - ⁇ , - ⁇ , in particular:
- S ⁇ edineniya 1-8 are ⁇ izv ⁇ dnymi ⁇ i ⁇ id ⁇ [2,3- ⁇ ] -6 ⁇ - ⁇ i ⁇ idazin-5,8 di ⁇ na, ⁇ luchali ⁇ -di ⁇ a ⁇ b ⁇ sizameschenny ⁇ ⁇ ndensatsiey ⁇ i ⁇ idin ⁇ v with gid ⁇ azin gid ⁇ a ⁇ m in s ⁇ ede u ⁇ susn ⁇ y ⁇ isl ⁇ y ( ⁇ a ⁇ shsY ⁇ ggozY.
- S ⁇ edineniya 19-28 are ⁇ izv ⁇ dnymi ⁇ i ⁇ azin ⁇ [2,3- ⁇ ] -6 ⁇ -5,8- ⁇ i ⁇ idazin- di ⁇ na, ⁇ luchali ⁇ -di ⁇ a ⁇ b ⁇ sizameschenny ⁇ ⁇ ndensatsiey ⁇ i ⁇ azin ⁇ v gid ⁇ azingid ⁇ a ⁇ m in s ⁇ ede u ⁇ susn ⁇ y ⁇ isl ⁇ y ( ⁇ us ⁇ u ⁇ zka -. ⁇ a ⁇ ak I., S ⁇ a ⁇ ka ⁇ , ⁇ . .
- SIGNIFICANT FOX (DR. 26) 15 In this way, it was possible to identify the varied components of the morphine absentinum, sensitive to compounds according to the invention. 2. Influence of compounds according to the invention on neutral indicators in the brain.
- the reaction was initiated by the addition of a cerebral agent in a reconstituted medium containing 2 ⁇ / ml [ 3 ⁇ ] L-arginine, 20 m ⁇ ⁇ ( ⁇ 7.4), 0.2 m ⁇ CaCl 2 , 5 ⁇ 50 m ⁇ , the study of brain brains.
- SIGNIFICANT FOX (DR. 26) 18 gypsy cam 2.55 3.10 3.09 2.70 2.51 2.33 2.65 ⁇ 0.12 ⁇ 0.20 ⁇ 0.16 ⁇ 0.14 ⁇ 0.19 ⁇ 0.11 ⁇ 0, 15 hypothalamus 5.37 3.42 5.45 5.26 5.36 5.47 5.56 ⁇ 0.20 ⁇ 0.54 ⁇ 0.24 ⁇ 0.28 ⁇ 0.33 ⁇ 0.32 ⁇ 0, 34
- the compounds according to the invention bought the activity of the EC in the hippostalamus, the middle brain and the hippocampus, which was disturbed by the morphine.
- Conclusions In general, for both the syndrome of the compound of the invention and the invention, administered in doses of 3x20 mg / kg are internally the following:
- Live group LJ 2-9 ( ⁇ 7), one of the compounds according to the invention, selected from the group of compounds 2, 8, 9, 15, 19, 25, 31, 36, was introduced inside the unit with a dose of 10 mg: with an interval between injections of 48 hours.
- the preparations were distributed in a 0.1% aqueous solution and then administered to all 0.1 mg / kg after a 24-hour follow-up.
- SIGNIFICANT FOX (DR. 26) 21 4.1.
- the cradle was placed for 3 min in the middle of the illuminated camera in the dark.
- a lively camcorder was found to be in the dark and left in the dark.
- the investigation of the biological features of the litter is preferable to be in a dark place.
- the latent interface was turned off before entering the dark camera ( ⁇ 1), then immediately after the passage, the rythro was disembarked from the dark camera. After 30 minutes of manipulation, they turned on and registered the latent switch to the dark camera ( ⁇ 2). More than 30 minutes later, the latent transition to the dark entrance (DZ) was registered and the two doors were turned off (live room).
- variable electric current 50 Hz, 80 ⁇
- the storage of the reaction of the company took place after 24 hours, 7 and 14 days.
- the cassette was placed in the installation for 3 minutes and the latent transition to the dark chamber was registered. Learning is a latent transient of at least 180 s. It is more convenient to stay in the illuminated part of the installation or to turn off the dark in the storage compartment.
- the labyrinth is located at a height of 70 cm from the floor. Placement in a soundproofed room. The course was placed in the middle of the installation and within 10 minutes the visually discharged number of entrances to the closed and empty labyrinth and the time spent in the hospital was taken away. Each living test was single. B).
- SIGNIFICANT FOX (DR. 26) 23 were issued within 5 minutes, one at a time. Statistical analysis was carried out using, in each case, suitable statistical tests. The results of the experiments are presented in Figures. 2a, 2b, 3a, 3b, 3c, 4a, 4b, where:
- the compounds according to the invention have a positive effect on the ability to learn livelihoods (cognitive function) and psychosocial disabilities.
- in general in general, there is an inconvenience to the fact that there is an imminent loss of natural biological systems.
- Experimental indications are that these connections may be used as a part of the neuroprocesses of a non-invasive system.
- the introduction of compounds according to the invention improves the cognitive function and psycho-physical state, decreasing the stability and distress.
- the compounds according to the invention improve the sexual function and also show the positive effect of the syndrome and the absolute syndrome.
- SIGNIFICANT FOX (DR. 26) 25 P ⁇ m ⁇ lennaya ⁇ imenim ⁇ s ⁇ Uchi ⁇ yvaya me ⁇ anizm deys ⁇ viya tsi ⁇ liches ⁇ i ⁇ bi ⁇ iz ⁇ s ⁇ e ⁇ v ⁇ izv ⁇ dny ⁇ ⁇ u ⁇ in ⁇ v ⁇ y sis ⁇ emy s ⁇ glasn ⁇ iz ⁇ b ⁇ e ⁇ eniyu and v ⁇ vlechenn ⁇ s ⁇ m ⁇ duli ⁇ uemy ⁇ them d ⁇ amine ⁇ giches ⁇ y and ni ⁇ e ⁇ giches ⁇ y sis ⁇ em in ⁇ a ⁇ genez ⁇ azlichny ⁇ zab ⁇ levany, m ⁇ zhn ⁇ za ⁇ lyuchi ⁇ , ch ⁇ vysheu ⁇ azannye s ⁇ edineniya m ⁇ gu ⁇ by ⁇ is ⁇ lz ⁇ vany to treat ⁇ yada zab ⁇ levany, v ⁇
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Genetics & Genomics (AREA)
- Reproductive Health (AREA)
- Child & Adolescent Psychology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Pulmonology (AREA)
- Obesity (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE602004021114T DE602004021114D1 (de) | 2003-08-04 | 2004-08-03 | Verwendung von cyclischen bioisosteren von purin-system-derivaten zur behandlung von erkrankungen durch störungen der nitrergen und dopaminergen systeme |
AT04775242T ATE431148T1 (de) | 2003-08-04 | 2004-08-03 | Verwendung von cyclischen bioisosteren von purin- system-derivaten zur behandlung von erkrankungen durch störungen der nitrergen und dopaminergen systeme |
EP04775242A EP1655028B1 (en) | 2003-08-04 | 2004-08-03 | Use of cyclic bioisosteres of purine system derivatives for the treatment of diseases caused by disorders of nitrergic and dopaminergic systems |
US10/567,113 US7776833B2 (en) | 2003-08-04 | 2004-08-03 | Use of cyclic bioisosters of purine system derivatives for treating diseases produced by disorders of niterergic and dopaminergic systems |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
RUPCT/RU03/00346 | 2003-08-04 | ||
PCT/RU2003/000346 WO2005012309A1 (en) | 2003-08-04 | 2003-08-04 | Cyclic bioisosters of purine system derivatives and a pharmaceutical composition based thereon |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2005011648A2 true WO2005011648A2 (en) | 2005-02-10 |
WO2005011648A3 WO2005011648A3 (fr) | 2005-08-04 |
Family
ID=34114562
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/RU2003/000346 WO2005012309A1 (en) | 2003-08-04 | 2003-08-04 | Cyclic bioisosters of purine system derivatives and a pharmaceutical composition based thereon |
PCT/RU2004/000298 WO2005011648A2 (en) | 2003-08-04 | 2004-08-03 | Use of cyclic bioisosteres of purine system derivatives for the treatment diseases caused by disorders of nitrergic and dopaminergic systems |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/RU2003/000346 WO2005012309A1 (en) | 2003-08-04 | 2003-08-04 | Cyclic bioisosters of purine system derivatives and a pharmaceutical composition based thereon |
Country Status (7)
Country | Link |
---|---|
US (2) | US8592421B2 (ru) |
EP (3) | EP1655301B1 (ru) |
AT (1) | ATE431148T1 (ru) |
AU (1) | AU2003301513A1 (ru) |
DE (1) | DE602004021114D1 (ru) |
UA (1) | UA85389C2 (ru) |
WO (2) | WO2005012309A1 (ru) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL231885B1 (pl) * | 2009-01-16 | 2019-04-30 | Abidopharma Spolka Z Ograniczona Odpowiedzialnoscia | Sposób wytwarzania soli 5-amino-2,3-dihydroftalazyno-1,4-di onu z metalami alkalicznymi, ich kompozycje farmaceutyczne i ich zastosowanie |
CA2791327C (en) | 2010-03-01 | 2018-10-30 | Metriopharm Ag | Crystalline forms of 5-amino-2,3-dihydrophthalazine-1,4-dione sodium salt, pharmaceutical preparations containing the same, method for production of said forms and use of said forms for modulating the immune system |
US9398642B2 (en) | 2012-10-22 | 2016-07-19 | Thales Canada Inc | Removable heater for communication antenna |
US9901342B2 (en) | 2015-03-06 | 2018-02-27 | Ethicon Endo-Surgery, Llc | Signal and power communication system positioned on a rotatable shaft |
Family Cites Families (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5046697A (ru) | 1973-08-20 | 1975-04-25 | ||
US4727079A (en) * | 1983-01-27 | 1988-02-23 | University Of Florida | Brain-specific dopaminergic activity involving dihydropyridine carboxamides, dihydroquinoline and isoquinoline carboxamides |
IL69132A (en) * | 1982-07-14 | 1986-02-28 | Roussel Uclaf | Benzo-and naphtho-thiopyranopyrimidinones,their preparation and pharmaceutical compositions containing them |
SE8302361D0 (sv) * | 1983-04-27 | 1983-04-27 | Astra Laekemedel Ab | New tricyclic amines |
US4548817A (en) * | 1984-01-20 | 1985-10-22 | Webb-Waring Lung Institute | Composition and method for treating mammalian acidosis |
US4600714A (en) * | 1984-04-26 | 1986-07-15 | Smithkline Beckman Corporation | Fenoldopam 4',8-bis-hydrogen sulfate and dopaminergic use thereof |
US4650805A (en) * | 1985-12-02 | 1987-03-17 | Warner-Lambert Company | 4-(1,2,5,6-Tetrahydro-1-alkyl-3-pyridinyl)-2-thiazolamines and 4-(hexahydro-1-alkyl-3-pyridinyl)-2-thiazolamines having anti-psychotic activity |
GB8610432D0 (en) * | 1986-04-29 | 1986-06-04 | Akzo Nv | Amino-thiazole & oxazole derivatives |
US4950602A (en) * | 1987-02-20 | 1990-08-21 | Cornell Research Foundation, Inc. | Inhibition of lactate production by pyruvate adducts |
RU2014077C1 (ru) | 1987-10-26 | 1994-06-15 | Одесский научно-исследовательский институт стоматологии | Средство для интегральной коррекции метаболического ацидоза и алколоза |
US5256660A (en) | 1987-12-14 | 1993-10-26 | Henry Swan Ii Trust | Synthetic buffer composition for clinical use |
CA1321751C (en) | 1989-02-21 | 1993-08-31 | Eugene C. Crichlow | Mechanism mediating ruminal stasis in ruminal lactic acidosis |
US5719151A (en) * | 1990-05-04 | 1998-02-17 | Shall; Sydney | Substituted benzene compounds |
EP0536279A1 (en) * | 1990-06-29 | 1993-04-14 | The Upjohn Company | Substituted 1-(alkoxyphenyl)piperazines with cns and antihypertensive activity |
JP3167762B2 (ja) | 1990-11-27 | 2001-05-21 | 武田薬品工業株式会社 | ピリドピリダジン誘導体およびその用途 |
US5723496A (en) | 1991-03-05 | 1998-03-03 | The Regents Of University Of California | Method for prevention and treatment of harmful effects of intracellular acidosis |
CH683965A5 (it) | 1993-02-19 | 1994-06-30 | Limad Marketing Exp & Imp | Composti della classe dei ftalidrazidici come sostanza attiva in agenti antinfiammatori ed antitossici. |
CH683966A5 (it) * | 1993-02-19 | 1994-06-30 | Limad Marketing Exp & Imp | Composti della classe dei ftalidrazidici come sostanze attive in agenti anti-ipossici e di difesa. |
GB9420590D0 (en) | 1993-10-22 | 1994-11-30 | Zeneca Ltd | Pyridazino quinoline compounds |
US5476855A (en) * | 1993-11-02 | 1995-12-19 | Mahmoud H. el Kouni | Enzyme inhibitors, their synthesis and methods for use |
US5589483A (en) * | 1994-12-21 | 1996-12-31 | Geron Corporation | Isoquinoline poly (ADP-ribose) polymerase inhibitors to treat skin diseases associated with cellular senescence |
TW372967B (en) * | 1994-12-27 | 1999-11-01 | Kanebo Ltd | 1,4 benzoxazine derivative, pharmaceutical composition containing the same and use thereof |
US5883094A (en) * | 1995-04-24 | 1999-03-16 | Pfizer Inc. | Benzimidazolone derivatives with central dopaminergic activity |
RU2108806C1 (ru) | 1995-05-10 | 1998-04-20 | Юсупов Салехжан Загидуллович | Способ коррекции иммунной системы |
RU2098086C1 (ru) | 1995-05-10 | 1997-12-10 | Муса Тажудинович Абидов | Способ диагностики онкологических заболеваний |
US5889010A (en) * | 1995-05-18 | 1999-03-30 | Pfizer Inc. | Benzimidazole derivatives having dopaminergic activity |
US5753706A (en) | 1996-12-16 | 1998-05-19 | Hsu; Chen Hsing | Methods for treating renal failure |
EP1004304A4 (en) * | 1996-12-24 | 2002-10-16 | Sumitomo Pharma | COMPOSITION WITH ACORBIC ACID |
GB9707693D0 (en) * | 1997-04-16 | 1997-06-04 | Smithkline Beecham Plc | Novel method of treatment |
RU2113222C1 (ru) | 1997-09-30 | 1998-06-20 | Закрытое акционерное общество "Центр современной медицины "Медикор" | Иммуномодулирующее средство |
RU2160104C2 (ru) | 1997-11-06 | 2000-12-10 | Закрытое акционерное общество "Центр современной медицины "Медикор" | Способ лечения язвенной болезни и лекарственный препарат для его осуществления |
RU2132189C1 (ru) | 1998-11-03 | 1999-06-27 | Закрытое акционерное общество "Абидофф-Фарма" | Способ лечения мастопатии и миомы матки |
RU2132685C1 (ru) | 1998-11-03 | 1999-07-10 | Закрытое акционерное общество "Абидофф-Фарма" | Способ лечения доброкачественной гиперплазии предстательной железы |
RU2132188C1 (ru) | 1998-11-03 | 1999-06-27 | Закрытое акционерное общество "Абидофф-Фарма" | Способ лечения гипофункции щитовидной железы |
RU2138264C1 (ru) | 1999-05-06 | 1999-09-27 | Абидов Муса Тажудинович | Способ получения лекарственного препарата галавит |
RU2163122C1 (ru) | 2000-08-01 | 2001-02-20 | Абидов Муса Тажудинович | Лекарственное средство |
EP1203587B1 (en) | 2000-03-28 | 2010-07-14 | Abidov, Musea Tazhudinovich | A medicament and method for the production thereof |
RU2155043C1 (ru) | 2000-03-28 | 2000-08-27 | Абидов Муса Тажудинович | Способ получения лекарственного препарата |
RU2169139C1 (ru) | 2000-08-02 | 2001-06-20 | Закрытое акционерное общество "Центр современной медицины "Медикор" | Способ получения щелочных и щелочноземельных солей 5-амино-2,3-дигидро-1,4-фталазиндиона |
RU2167659C1 (ru) | 2000-08-02 | 2001-05-27 | Закрытое акционерное общество "Центр современной медицины "Медикор" | Способ коррекции иммунной системы живого организма |
US6521623B1 (en) * | 2000-09-19 | 2003-02-18 | Boehringer Ingelheim Pharma Kg | N,N'-disubstituted benzimidazolone derivatives with affinity at the serotonin and dopamine receptors |
RU2185173C2 (ru) | 2000-09-20 | 2002-07-20 | Государственный институт кровезаменителей и медицинских препаратов | Препарат гемодинамического действия с функцией нормализации кислотно-основного равновесия и электролитного баланса |
RU2211036C2 (ru) * | 2001-11-20 | 2003-08-27 | Общество с ограниченной ответственностью "Абидофарма" | Лекарственный препарат (варианты) и способ его производства |
US6953799B1 (en) * | 2002-10-30 | 2005-10-11 | Bach Pharma, Inc. | Modulation of cell fates and activities by diketo phthalazines |
-
2003
- 2003-08-04 AU AU2003301513A patent/AU2003301513A1/en not_active Abandoned
- 2003-08-04 EP EP03817813.3A patent/EP1655301B1/en not_active Expired - Lifetime
- 2003-08-04 WO PCT/RU2003/000346 patent/WO2005012309A1/ru active Application Filing
- 2003-08-04 US US10/567,114 patent/US8592421B2/en active Active
-
2004
- 2004-08-03 US US10/567,113 patent/US7776833B2/en not_active Expired - Fee Related
- 2004-08-03 WO PCT/RU2004/000298 patent/WO2005011648A2/ru active Application Filing
- 2004-08-03 EP EP04775242A patent/EP1655028B1/en not_active Expired - Fee Related
- 2004-08-03 DE DE602004021114T patent/DE602004021114D1/de active Active
- 2004-08-03 EP EP09004780.4A patent/EP2074998B1/en active Active
- 2004-08-03 UA UAA200602341A patent/UA85389C2/ru unknown
- 2004-08-03 AT AT04775242T patent/ATE431148T1/de not_active IP Right Cessation
Non-Patent Citations (4)
Title |
---|
BLASIG J.; HERZ A.; REINHOLD K.: "Zieglgansberger S. Development of physical dependence on morphine in respect to time and dosage and quantification of the precipitated withdrawal syndrome in rats", PSYCHOPHARMACOLOGIA, BERLIN, vol. 33, 1973, pages 19 - 38 |
DUM J; BLASIG J; HERZ A: "Buprenorphine: demonstration of physical dependence liability", EUR. J. PHARMACOL., vol. 70, 1981, pages 293 - 300 |
RAHMAN S.; ALI KHAN R.: "Kumar A. Experimental study of the morphine de-addiction properties of Delphinium denudatum Wall", BMC COMPLEMENT ALTERN. MED., vol. 29, 2002, pages 1 - 6 |
RAHMAN S.; ALI KHAN R.; KUMAR A.: "Experimental study of the morphine de-addiction properties of Delphinium denudatum Wall", BMC COMPLEMENT ALTERN. MED., vol. 29, 2002, pages 1 - 6 |
Also Published As
Publication number | Publication date |
---|---|
EP1655301B1 (en) | 2015-03-11 |
WO2005012309A1 (en) | 2005-02-10 |
UA85389C2 (ru) | 2009-01-26 |
EP2074998A3 (en) | 2009-10-07 |
US20080194501A1 (en) | 2008-08-14 |
WO2005011648A3 (fr) | 2005-08-04 |
US20070135636A1 (en) | 2007-06-14 |
EP2074998B1 (en) | 2013-10-16 |
US8592421B2 (en) | 2013-11-26 |
US7776833B2 (en) | 2010-08-17 |
ATE431148T1 (de) | 2009-05-15 |
EP1655301A4 (en) | 2007-09-19 |
DE602004021114D1 (de) | 2009-06-25 |
EP1655028B1 (en) | 2009-05-13 |
EP1655028A2 (en) | 2006-05-10 |
EP2074998A2 (en) | 2009-07-01 |
AU2003301513A1 (en) | 2005-02-15 |
EP1655301A1 (en) | 2006-05-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Leavitt | Drugs and behavior | |
Satora et al. | Fly agaric (Amanita muscaria) poisoning, case report and review | |
WO1997015225A1 (fr) | Agent therapeutique contre les troubles neurodegeneratifs | |
Shyngle | Chronic intake of separate and combined alcohol and nicotine on body maintenance among albino rats | |
Le Gassicke et al. | The clinical state, sleep and amine metabolism of a tranylcypromine (‘Parnate’) addict | |
WO2011146726A1 (en) | Methods and formulations for oxytocin treatment of substance use, psychiatric and other disorders | |
WO1993013764A1 (en) | Pharmaceutical preparation of antistress, stress-preventive and nootropic action | |
Jackson et al. | Delirium associated with clozapine and benzodiazepine combinations | |
WO1995017902A1 (fr) | Utilisation d'une souche du champignon fusarium comme producteur de substances et preparation a base celle-ci presentant, des proprietes, adaptogeniques et immunomodulatrices | |
WO2005011648A2 (en) | Use of cyclic bioisosteres of purine system derivatives for the treatment diseases caused by disorders of nitrergic and dopaminergic systems | |
Molina et al. | Infantile sensitivity to ethanol's motivational effects: Ethanol reinforcement during the third postnatal week | |
Mayron | Allergy, learning, and behavior problems | |
Carpenter | The Nobel Prize and the discovery of vitamins | |
WO2001064228A1 (fr) | Procede de production d'une substance biologiquement active a partir du serum sanguin | |
Bouchard | Lectures on Auto-intoxication in Disease: Or, Self-poisoning of the Individual | |
White et al. | Caffeine-induced taste aversion and mimetic responses | |
WO1993000892A1 (en) | Pharmaceutical preparation | |
Guenther | Conditioned aversive responses produced by delayed, but not immediate, exposure to cocaine in male Sprague-Dawley rats | |
RU2783441C1 (ru) | Курсовое применение тразодона сукцината для лечения сепарационной тревоги у собак | |
Yadav | Pharmacology & Toxicology | |
CN102316865A (zh) | 用于改善正常的认知功能的l-赖氨酸 | |
WO1996021446A1 (fr) | Composition pharmaceutique a proprietes antialcooliques et nootropes | |
WO1989002745A1 (en) | Pharmaceutical preparation for curing multiple sclerosis and lateral amyotrophic sclerosis | |
Shuttleworth | Zinc—in perspective | |
WO1998040103A1 (fr) | Procede visant a renforcer l'effet therapeutique et a reduire la toxicite de medicaments, de metaux ainsi que de composes organiques ou inorganiques |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DPEN | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2007135636 Country of ref document: US Ref document number: 10567113 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004775242 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006102587 Country of ref document: RU |
|
WWP | Wipo information: published in national office |
Ref document number: 2004775242 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 10567113 Country of ref document: US |